Stoke Therapeutics (STOK) – Investment Analysts’ Weekly Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Stoke Therapeutics (NASDAQ: STOK) in the last few weeks:

• 8/7/2026 – Stoke Therapeutics had its “sell (d)” rating reaffirmed by Weiss Ratings.
• 8/4/2026 – Stoke Therapeutics had its “buy” rating reaffirmed by Guggenheim. They now have a $60.00 price target on the stock.
• 8/4/2026 – Stoke Therapeutics had its price target raised by Wedbush from $38.00 to $40.00. They now have an “outperform” rating on the stock.
• 8/4/2026 – Stoke Therapeutics had its price target lowered by Canaccord Genuity Group Inc. from $60.00 to $58.00. They now have a “buy” rating on the stock.
• 8/4/2026 – Stoke Therapeutics had its “buy” rating reaffirmed by Chardan Capital. They now have a $35.00 price target on the stock.
• 7/13/2026 – Stoke Therapeutics is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $44.00 price target on the stock.
• 7/13/2026 – Stoke Therapeutics is now covered by The Goldman Sachs Group, Inc.. They set a “buy” rating and a $44.00 price target on the stock.

Insider Transactions at Stoke Therapeutics

In related news, General Counsel Jonathan Allan sold 1,457 shares of the firm’s stock in a transaction dated Tuesday, June 16th. The shares were sold at an average price of $29.95, for a total value of $43,637.15. Following the completion of the sale, the general counsel owned 18,086 shares in the company, valued at $541,675.70. This trade represents a 7.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Barry Ticho sold 7,176 shares of the business’s stock in a transaction dated Monday, August 3rd. The stock was sold at an average price of $29.04, for a total transaction of $208,391.04. Following the sale, the insider directly owned 20,422 shares in the company, valued at approximately $593,054.88. This represents a 26.00% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 10,428 shares of company stock valued at $306,919 in the last quarter. Insiders own 9.60% of the company’s stock.

Stoke Therapeutics, headquartered in Bedford, Massachusetts, is a clinical-stage biopharmaceutical company focused on developing genetic medicines to upregulate protein production for the treatment of rare neuromuscular and neurological disorders. Founded in 2014, the company applies its proprietary Targeted Augmentation of Nuclear Gene Output (TANGO™) platform to design antisense oligonucleotides that selectively modulate RNA splicing and enhance expression of functional proteins.

The company’s lead program, STK-001, is an antisense oligonucleotide therapy designed to increase production of the sodium channel protein SCN1A and is currently in clinical development for Dravet syndrome, a severe childhood-onset epilepsy.